Business Continuity and Earnings Impact Risk from COVID-19
First written in FY2020. 12 of 17 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2026RaisedAnnual report
「If the Group becomes unable to supply products and merchandise stably due to supply-chain disruptions arising from the manifestation of geopolitical risks or the spread of emerging infectious diseases, or if prolonged economic effects affect the business activities of customers and partner companies, this could materially affect the Group’s operating results and other matters.」
The risk description, previously focused on emerging infectious diseases and other illnesses, now explicitly includes supply chain disruptions arising from the emergence of geopolitical risks, broadening the scope of business continuity and supply stoppage risks. - FY2025ReframedAnnual report
「The spread of emerging infectious diseases and other illnesses may prevent the stable supply of products and merchandise. In addition, if the economic impact is prolonged and the business activities of customers or partner companies are affected, this may have a material impact on the Group's business results and other matters.」
The description has been revised from focusing primarily on COVID-19 to covering "emerging infectious diseases and other illnesses," with supply stoppages and impacts on customers and partner companies identified as risks. - FY2024RestatedAnnual report
「The spread of infectious diseases, including COVID-19, may prevent the stable supply of products and merchandise. In addition, if the economic impact is prolonged and the business activities of customers or partner companies are affected, this may have a material impact on the Group's business results and other matters.」
The company reaffirms the possibility that supply stoppages and impacts on customers and partner companies caused by infectious diseases in general, including COVID-19, may affect performance. - FY2024-Q3RestatedAnnual report
「During the first nine months of the current consolidated fiscal year, Japan's economy was on a trend of gradual recovery from the impact of COVID-19, but uncertain conditions continued amid concerns over the impact ahead of soaring resource prices resulting from international conditions and other factors, as well as monetary tightening in Europe and the United States in response to rising prices.」
Although the company states that it is on a recovery trend from the impact of infectious diseases, it reports that uncertainty in the economic environment, including the impact of infectious diseases, continues. - FY2023RaisedAnnual report
「The spread of infectious diseases, including COVID-19, may prevent the stable supply of products and merchandise. In addition, if the economic impact is prolonged and the business activities of customers or partner companies are affected, this may have a material impact on the Group's business results and other matters.」
The scope has been expanded from the previous COVID-19 risk to include supply stoppages caused by infectious diseases in general and impacts on customers and partner companies. - FY2023-Q3RestatedAnnual report
「During the first nine months of the current consolidated fiscal year, Japan's economy remained difficult due to the resurgence of COVID-19, soaring resource prices resulting from international conditions and other factors, and the impact of exchange rates, and uncertain conditions are expected to continue ahead.」
The company reaffirms the severe business environment, including a resurgence of COVID-19, and uncertainty about the outlook arising from infectious diseases, international conditions, resource prices and foreign exchange rates. - FY2023-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, Japan's economy remained difficult due to the resurgence of COVID-19, soaring resource prices resulting from international conditions and other factors, and the impact of exchange rates, and uncertain conditions are expected to continue ahead.」
The company reaffirms the severity of the business environment and uncertainty about the outlook due to the resurgence of COVID-19, soaring resource prices and the impact of foreign exchange rates. - FY2023-Q1RestatedAnnual report
「During the first three months of the current consolidated fiscal year, although the COVID-19 situation showed signs of stabilizing, uncertain conditions are expected to continue ahead due to a resurgence of infections and soaring resource prices resulting from international conditions and other factors.」
Although the COVID-19 situation is showing signs of settling, uncertainty about the outlook, including the possibility of a renewed spread of the infection, continues. - FY2022RestatedAnnual report
「As of the end of March 2022, the company held more than ¥64 billion in cash and deposits and therefore recognized that no liquidity concerns were likely to arise. However, as there are concerns that the economic impact may be prolonged due to the spread of the infection, if the business activities of customers or partner companies are affected, this may have a material impact on the Group's business results and other matters.」
The company reaffirms the impact on performance of a prolonged economic impact from COVID-19 and disruptions to the activities of customers and partner companies, and indicates that cash and deposits of more than ¥64 billion support its view that liquidity is not a concern. - FY2022-Q3RestatedAnnual report
「In the healthcare industry, while strengthening the response to COVID-19, companies are required to build an efficient healthcare delivery system through the functional differentiation and coordination of medical institutions under regional healthcare planning.」
The company describes the continued response to COVID-19 and the requirement to build an efficient healthcare delivery system through regional healthcare planning. - FY2022-Q2RestatedAnnual report
「In the medical equipment industry, while strengthening the response to COVID-19, companies are required to build an efficient healthcare delivery system through the functional differentiation and coordination of medical institutions under regional healthcare planning.」
The company describes the continuing burden on medical institutions resulting from the response to COVID-19 and the requirement to build an efficient healthcare delivery system. - FY2022-Q1RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2020 were revised upward overall. However, medical institutions continue to face significant burdens due to the renewed spread of COVID-19.」
The company reaffirms that the burden on medical institutions caused by the resurgence of COVID-19 continues. - FY2021RestatedAnnual report
「However, as there are concerns that the economic impact may be prolonged due to the spread of the infection, if the business activities of customers or partner companies are affected, this may have a material impact on the Group's business results and other matters.」
The company reaffirms the possibility that a prolonged economic impact from COVID-19 and disruptions to the activities of customers and partner companies may affect performance. At the same time, it states that cash and deposits of more than ¥56.5 billion as of the end of March 2021 pose no liquidity concerns. - FY2021-Q3RestatedAnnual report
「During the first nine months of the current consolidated fiscal year, Japan's economy remained difficult due to the impact of COVID-19, and uncertain conditions are expected to continue ahead.」
The company reaffirms that the impact of COVID-19 is continuing and that economic and business conditions remain severe and uncertain. - FY2021-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, Japan's economy remained difficult due to the impact of COVID-19, and uncertain conditions are expected to continue ahead.」
The company reaffirms that the economic impact of COVID-19 is continuing and that the outlook remains uncertain. - FY2021-Q1MaterialisedAnnual report
「During the first three months of the current consolidated fiscal year, Japan's economy deteriorated rapidly due to the global spread of COVID-19, and difficult, uncertain conditions are expected to continue ahead.」
Regarding the potential impact of COVID-19 on performance reported in the previous fiscal year, a rapid deterioration in the economy due to its global spread and the significant burden on medical institutions are now described as actual conditions. - FY2020First statedAnnual report
「However, as there are concerns that the economic impact may be prolonged due to the spread of the infection, if the business activities of customers or partner companies are affected, this may have a material impact on the Group's business results and other matters.」
With the global spread of COVID-19, employee infections, prolonged isolation, disruptions to the activities of customers and partner companies, and a prolonged economic impact are identified for the first time as independent risks that may affect business continuity and performance. The company also states that, with cash and deposits of more than ¥49.1 billion, it does not expect liquidity concerns to arise.